Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 6/20 | 0.35 |
| ▸ | CTSS | P25774 | 5/20 | 0.35 |
| ▸ | CTSV | O60911 | 1/20 | 0.35 |
| ▸ | GPR132 | Q9UNW8 | 6/20 | 0.34 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 6/20 | 0.32 |
| ▸ | FNTA | P49354 | 1/20 | 0.32 |
| ▸ | FNTB | P49356 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4684645 | 0.94 | CTSL (0.38) | CTSLCTSSCTSVGPR132CTSB | |
| Trifluoroacetic Acid SCHEMBL4681491 | 0.93 | SLC2A1 (0.34) | CTSLCTSSSLC2A1CTSBHDAC1 | |
| SCHEMBL4685038 | 0.92 | KAT6A (0.36) | CTSLCTSSCTSBFNTAFNTB | |
| SCHEMBL4687000 | 0.92 | KAT6A (0.36) | CTSLCTSSCTSBFNTAFNTB | |
| SCHEMBL4686997 | 0.92 | KAT6A (0.36) | CTSLCTSSCTSBFNTAFNTB | |
| Trifluoroacetic Acid SCHEMBL4681505 | 0.90 | F10 (0.38) | CTSLCTSSSLC2A1CTSB | |
| Trifluoroacetic Acid SCHEMBL4681030 | 0.86 | PIN1 (0.33) | — | |
| SCHEMBL4685358 | 0.86 | CYP3A4 (0.32) | GPR132FNTAFNTBHDAC1 | |
| SCHEMBL4685355 | 0.86 | CYP3A4 (0.32) | GPR132FNTAFNTBHDAC1 | |
| SCHEMBL4685353 | 0.86 | CYP3A4 (0.32) | GPR132FNTAFNTBHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1236712-B1 | AMIDINOPHENYLPYRUVIC ACID DERIVATIVE | AJINOMOTO KK (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-6710056-B2 | PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF HAVE AN EXCELLENT ANTAGONISTIC EFFECT AGAINST ACTIVATED BLOOD COAGULATION FACTOR VII. | AJINOMOTO CO., INC. (JP) | 2004-03-23 | — | — | US | disclosed |
| US-20030109547-A1 | Amidinophenylpyruvic acid derivatives | AJINOMOTO CO. INC (JP) | 2003-06-12 | — | — | US | disclosed |
| EP-1236712-A1 | AMIDINOPHENYLPYRUVIC ACID DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2002-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109547-A1 | Amidinophenylpyruvic acid derivatives | HABP2, F2, F7 | CTSL 703/4885CTSS 1896/4885CTSV 1871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.